Protein-losing enteropathy (PLE), the excessive loss of plasma proteins through the intestine, often correlates with the episodic loss of heparan sulfate (HS) proteoglycans (HSPG) from the basolateral surface of intestinal epithelial cells. PLE onset is often associated with a proinflammatory state. We investigated whether loss of HS or treatment with the pro-inflammatory cytokine TNFα directly causes protein leakage, and whether a combination of both exacerbates Our findings imply that loss of HSPGs renders patients more susceptible for PLE and offer a potential explanation for the favorable response some PLE patients have to heparin therapy.
Introduction
Protein-losing enteropathy (PLE) is defined as the enteric loss of plasma proteins, which can exceed 20 g/day (1) . PLE is not a disease itself, but a symptom in several ostensibly unrelated diseases, including Crohn's Disease (1), Congenital Disorders of Glycosylation (CDG) (36) , and as a long term complication of Fontan surgeries to correct congenital heart malformations (16) . In CDG and post-Fontan patients PLE is episodic and heparan sulfate proteoglycans (HSPG) on the basolateral surface of intestinal epithelial cells are absent or mislocalized during these episodes (18, 19, 29, 36) . In addition, PLE onset is often associated with a pro-inflammatory state (15, 36) , suggesting that multiple factors combine to exceed critical thresholds. However, mechanisms that link PLE with loss of HSPG and a pro-inflammatory state are yet unknown.
Heparan sulfate (HS) is a large, highly sulfated glycosaminoglycan (GAG) composed of alternating units of α-N-acetylglucosamine and β-glucuronic acid (12) . These chains are assembled in the Golgi on specific core proteins, termed heparan sulfate proteoglycans (HSPG).
These molecules are well established as an important barrier against protein leakage from the kidney and are absent from the glomerulus in patients with nephrotic syndrome (10, 23 showed an absence of enterocyte HSPG expression specifically from the basolateral surface of small intestinal epithelial cells. Overall intestinal architecture and other matrix components including laminin, collagen-I, and proteoglycans synthesized by other cells within the lamina propria remained intact and normal (19) .
Since then, absence of HSPGs from the basolateral surface of intestinal epithelial cells has been described in several other diseases associated with PLE. Histological assessment of small Bode -4 -bowel biopsies from a CDG-Ic-patient with PLE was mostly normal, but HSPGs were completely absent from the basolateral surfaces of epithelial cells. A second biopsy, taken after PLE resolved, showed a considerably improved basolateral HSPG staining pattern. All biopsies showed normal basolateral HSPG staining in the patient's colon, stomach, and esophagus, suggesting that the pathology was restricted to the small intestine (36) . Recently, we found that other CDG-Ia, Ib and Ic patients with PLE also lack basolateral HSPGs (Murch, unpublished data). Also, mannose treatment of CDG-Ib patients relieves PLE (21) and improves HSPG staining (Murch, unpublished data) . Moreover, duodenal biopsies from 5 out of 6 post-Fontan patients with PLE revealed strikingly reduced HSPG expression on the basolateral surface of intestinal epithelial cells while HSPG staining in lamina propria cells was normal (29) .
PLE or increased intestinal permeability may be triggered by infection (15, 36) and are often associated with a pro-inflammatory state (2, 3, 7, 8, 24, 34) . An elevated systemic concentration of the pro-inflammatory cytokine TNFα (22) as well as increased intestinal levels of interferon-gamma (IFNγ) (32) have been associated with PLE.
Half of the patients who develop PLE months to years after Fontan surgery have a fatal outcome. Therapeutic options for post-Fontan PLE are limited. Albumin infusions are used in severe cases (27) . The inflammatory aspect of PLE is commonly treated with long-term, high doses of anti-inflammatory steroids, but serious undesirable side effects appear (35) .
Subcutaneous injections of high molecular weight heparin reverse PLE in some patients (5, 11, 17, 28) , especially when given early after onset, but the basis and mechanism of heparin improvement are yet unknown (4).
Patient susceptibility to PLE, its cause, the underlying cellular and molecular mechanisms, and a rational basis for treating this condition, all suffer the absence of a fundamental Emission: 538 nm). Albumin flux through the untreated monolayer is defined as 1.0.
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Transepithelial electrical resistance (TER)
We monitored the integrity of the monolayer before and after different interventions by measuring TER with an Epithelial Voltohmmeter and STX2 electrodes (WPI, Sarasota, FL). TER in the untreated monolayer is defined as 100% after correcting for the resistance of a filter in tissue culture media without cells.
Radiolabeling of GAGs
To determine the GAG turnover rate in HT29 cells, we labeled them with Na 
Statistical analysis
Results are given as means ± SD from three independent experiments. Differences between interventions were tested by the two-tailed Student t test. P<0.05 is considered significant.
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Results
In vitro monolayer of intestinal epithelial cells
Five days after seeding the HT29 cells, TER was maximal (214.3±1.4 Ω x cm 2 , defined as 100%). We concluded that the cells had grown into a confluent monolayer and confirmed this by microscopic observation. To determine monolayer polarity, we used confocal microscopy to visualize the expression of the apical surface marker dipeptidylpeptidase IV (DPP IV) at day 5.
DPP IV was only expressed on the cell surface facing the media, defining the apical side, but it was not expressed on the cell surface facing the porous membrane of the insert (data not shown), 
Loss of HS causes protein leakage
Our first aim was to determine whether the loss of HS from the basolateral surface of intestinal epithelial cells caused protein leakage, as seen in patients with PLE. We incubated the basolateral surface of the HT29 monolayer with HSase (0.6 mU/mL, 2. Treatment with chondroitinase ABC (0.6 mU/mL) to specifically cleave chondroitin sulfate only slightly increased protein leakage 1.21±0.11-fold (P<0.05) and decreased TER 9.9±4.5%
(P<0.05), which was significantly less pronounced than the effects seen after HSase treatment (P<0.001). The combined effects of HSase and chondroitinase did not exceed the effects of HSase alone (data not shown).
TNFα causes protein leakage
PLE is often associated with a pro-inflammatory state (2, 3, 7, 8, 22, 24, 32, 34) . We therefore investigated whether the pro-inflammatory cytokine TNFα affects protein leakage and To investigate the time course of this synergism, we pretreated the cells with HSase as before and subsequently incubated the cells with TNFα (2 and 20 ng/mL) for 2-16 h. We found the greatest synergistic effects after 8 h with a 4.60±0.02-fold and a 7.00±0.11-fold increase in albumin flux for 2 and 20 ng/mL TNFα, respectively. After 16 h, the synergistic effects were less but still significant (Figure 7B-C) . We hypothesized that this decrease occurred because the HS molecules reappeared on the cell surface due to de novo synthesis (see also Figure 4A ). Addition of β-xyloside to block GAG-chain synthesis from the beginning of the experiment indeed maintained the large synergistic effects after 16 h (P<0.001 compared to treatment with HSase and TNFα, but without the addition of β-xylosides) (Figure 7B-C) .
We co-incubated the untreated or HSase/β-xyloside-pretreated cells with TNFα and either genistein or GM6001. Genistein blocked TNFα-induced albumin flux almost completely in both the untreated and the HSase/β-xyloside-pretreated cells. GM6001 partially blocked TNFα-Bode -14 -induced albumin flux (~50%), but to the same percentage in both the untreated and the HSase/β-xyloside-pretreated cells (data not shown).
Soluble HS and heparin abolish synergism
We have shown that cell-associated HS plays a role in preventing protein leakage and that its loss synergizes with TNFα to exacerbate protein leakage. Next we asked whether adding soluble HS to HSase digested cells affects the synergism. We pretreated the cells with HSase and β-xyloside as before and subsequently co-incubated the washed cells with TNFα and different sHS concentrations (0.1-100 µg/mL). Increasing sHS concentrations (k i~2 .5 µg/mL) did alleviate the synergistic effects on albumin flux ( Figure 8A ) and TER (data not shown), and 6.25 µg/mL completely abolished it. Higher sHS concentrations reduced the effects on albumin flux even below the level seen after TNFα treatment when cell-associated HS is present.
Polymeric sHS is required since digesting it to disaccharides with HSase had almost no effect on albumin flux and TER. The same concentration of heparin had a more pronounced effect than sHS, while soluble CS (sCS) had lesser effects (Figure 8A-B) . Addition of heparin also alleviates TNFα-induced protein-leakage when cell-associated HS is present on the cell surface ( Figure 8A ).
The mitigating effects of heparin are diminished when added hours after TNFα is added 
Studies with Caco-2 cells
To verify that our data is not specific for HT29, we repeated key experiments (similar to figures 1, 2, 4, 7, and 8) with Caco-2, another frequently used intestinal epithelial cell line, and got similar results (data not shown).
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Discussion
PLE occurs in seemingly unrelated diseases (1, 16, 36) and the only known common histological feature to date is loss of HS from the basolateral surface of intestinal epithelial cells (18, 19, 29, 36) . Whether this is cause or effect is unknown. To address this question, we established the first in vitro PLE-like model of protein leakage using a confluent, polarized monolayer of HT29 cells, an intestinal epithelial cell line often used to study intestinal permeability (20, 25, 31, 33) . In this model removal of HS directly causes protein leakage and decreases the integrity of the monolayer (Figure 1 and 2 ). HSase specifically degraded HS (as confirmed by competition with sHS, but not sCS) reducing cell-associated GAGs by 77%. Only treatment of the basolateral, but not the apical surface, induces protein leakage. We used confocal microscopy to confirm that HS is predominantly expressed on the basolateral surface of the HT29 monolayer (data not shown), which is in accordance with in vivo staining patterns of intestinal biopsies (18, 19, 36) . Loss of HS causes bi-directional protein leakage indicating that it might not only be important for inside-out protein leakage in the context of PLE, but also for impaired barrier function for outside-in traffic.
The sulfate groups on HS are important to prevent protein leakage as shown by increased albumin flux after chlorate treatment. However, other portions of the HS molecule, e.g. the uronic acids, help prevent protein loss, since complete loss of HS chains after treatment with HSase or β-xyloside increases protein leakage even more ( Figure 3 ).
PLE or increased permeability is often associated with a pro-inflammatory state (2, 3, 7, 8, 15, 24, 34, 36) . One of the predominant pro-inflammatory cytokines, TNFα, compromises epithelial barrier function, e.g. by the disruption of tight junctions (31) . We have indeed shown that TNFα induces protein leakage and reduces the integrity of the monolayer in our in vitro Bode -17 -model ( Figure 4 ). These effects are partially mediated by MMPs (Figure 6 ), but HSPGs are only slightly shed after TNFα-treatment ( Figure 5 ). This result suggests that other MMP-targets are involved and it also implies that TNFα and HS loss increase protein leakage by different mechanisms. We confirmed that TNFα does not induce cytotoxic or apoptotic mechanisms in HT29 cells at concentrations and incubation times used in this study (31) .
TNFα was ineffective when added to the apical side, which is in accordance with previous reports and can be explained by the polarized expression of TNFR1 on the basolateral surface Our results provide the first evidence that heparin also alleviates the TNFα-induced onset at the earliest stages of protein leakage. This is concordant with clinical observations that heparin injections reverse PLE, especially when given early after its onset (5, 11, 17, 28) .
Our data suggests direct interactions between heparin and TNFα or its receptors. Previous reports show that heparin binds to TNFα (9, 14) , but has no affinity for TNFα-binding-protein I, a soluble fragment of TNFR1 (14) . HSase was applied to either the basolateral surface (bl), the apical surface (ap), or both (ap+bl).
Mean and standard deviations from three independent experiments are shown. 
